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Abstract: Background Radiomic features may quantify characteristics present in medical imaging. How-
ever, the lack of standardized definitions and validated reference values have hampered clinical use.
Purpose To standardize a set of 174 radiomic features. Materials and Methods Radiomic features were
assessed in three phases. In phase I, 487 features were derived from the basic set of 174 features. Twenty-
five research teams with unique radiomics software implementations computed feature values directly
from a digital phantom, without any additional image processing. In phase II, 15 teams computed values
for 1347 derived features using a CT image of a patient with lung cancer and predefined image processing
configurations. In both phases, consensus among the teams on the validity of tentative reference values
was measured through the frequency of the modal value and classified as follows: less than three matches,
weak; three to five matches, moderate; six to nine matches, strong; 10 or more matches, very strong. In
the final phase (phase III), a public data set of multimodality images (CT, fluorine 18 fluorodeoxyglucose
PET, and T1-weighted MRI) from 51 patients with soft-tissue sarcoma was used to prospectively assess
reproducibility of standardized features. Results Consensus on reference values was initially weak for 232
of 302 features (76.8%) at phase I and 703 of 1075 features (65.4%) at phase II. At the final iteration,
weak consensus remained for only two of 487 features (0.4%) at phase I and 19 of 1347 features (1.4%) at
phase II. Strong or better consensus was achieved for 463 of 487 features (95.1%) at phase I and 1220 of
1347 features (90.6%) at phase II. Overall, 169 of 174 features were standardized in the first two phases.
In the final validation phase (phase III), most of the 169 standardized features could be excellently re-
produced (166 with CT; 164 with PET; and 164 with MRI). Conclusion A set of 169 radiomics features
was standardized, which enabled verification and calibration of different radiomics software. © RSNA,
2020 Online supplemental material is available for this article. See also the editorial by Kuhl and Truhn
in this issue.
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Background: Radiomic features may quantify characteristics present in medical imaging. However, the lack of standardized defini-
tions and validated reference values have hampered clinical use.
Purpose: To standardize a set of 174 radiomic features.
Materials and Methods: Radiomic features were assessed in three phases. In phase I, 487 features were derived from the basic set of 174 
features. Twenty-five research teams with unique radiomics software implementations computed feature values directly from a digi-
tal phantom, without any additional image processing. In phase II, 15 teams computed values for 1347 derived features using a CT 
image of a patient with lung cancer and predefined image processing configurations. In both phases, consensus among the teams on 
the validity of tentative reference values was measured through the frequency of the modal value and classified as follows: less than 
three matches, weak; three to five matches, moderate; six to nine matches, strong; 10 or more matches, very strong. In the final 
phase (phase III), a public data set of multimodality images (CT, fluorine 18 fluorodeoxyglucose PET, and T1-weighted MRI) from 
51 patients with soft-tissue sarcoma was used to prospectively assess reproducibility of standardized features.
Results: Consensus on reference values was initially weak for 232 of 302 features (76.8%) at phase I and 703 of 1075 features (65.4%) 
at phase II. At the final iteration, weak consensus remained for only two of 487 features (0.4%) at phase I and 19 of 1347 features 
(1.4%) at phase II. Strong or better consensus was achieved for 463 of 487 features (95.1%) at phase I and 1220 of 1347 features 
(90.6%) at phase II. Overall, 169 of 174 features were standardized in the first two phases. In the final validation phase (phase III), 
most of the 169 standardized features could be excellently reproduced (166 with CT; 164 with PET; and 164 with MRI).
Conclusion: A set of 169 radiomics features was standardized, which enabled verification and calibration of different radiomics software.
© RSNA, 2020
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noninvasive, readily available in clinical care, and repeat-
able (3,4).
Radiomics extracts features from medical imaging that 
quantify its phenotypic characteristics in an automated, 
high-throughput manner (5). Such features may help 
P
ersonalization of medicine is driven by the need to ac-
curately diagnose disease and define suitable treatments 
for patients (1). Medical imaging is a potential source of 
biomarkers because it provides a macroscopic view of tis-
sues of interest (2). Imaging has the advantage of being 
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Abbreviations
IBSI = Image Biomarker Standardization Initiative, ROI = region of 
interest
Summary
The Image Biomarker Standardization Initiative validated consensus-
based reference values for 169 radiomics features, thus enabling cali-
bration and verification of radiomics software.
Key Results
 n Twenty-five research teams found agreement for calculation of 
169 radiomics features derived from a digital phantom and a CT 
scan of a patient with lung cancer.
 n Among these 169 standardized radiomics features, good to excel-
lent reproducibility was achieved for 167 radiomics features using 
MRI, fluorine 18 fluorodeoxyglucose PET, and CT images ob-
tained in 51 patients with soft-tissue sarcoma.
prognosticate, predict treatment outcomes, and assess tissue ma-
lignancy in cancer research (6–9). In neuroscience, features may 
help detect Alzheimer disease (10) and diagnose autism spec-
trum disorder (11).
Despite the growing clinical interest in radiomics, pub-
lished studies have been difficult to reproduce and validate 
(5,9,12–14). Even for the same image, two different software 
implementations will often produce different feature values. 
This is because standardized definitions of radiomics features 
with verifiable reference values are lacking, and the image pro-
cessing schemes required to compute features are not imple-
mented consistently (15–18). This is exacerbated by reporting 
that is insufficiently detailed to enable studies and findings to 
be reproduced (19).
We formed the Image Biomarker Standardization Initiative 
(IBSI) to address these challenges by fulfilling the following objec-
tives: (a) to establish nomenclature and definitions for commonly 
used radiomics features; (b) to establish a general radiomics image 
processing scheme for calculation of features from imaging; (c) to 
provide data sets and associated reference values for verification 
and calibration of software implementations for image process-
ing and feature computation; and (d) to provide a set of reporting 
guidelines for studies involving radiomic analyses.
Materials and Methods
Study Design
We divided the current work into three phases (Fig 1). The first 
two phases focused on iterative standardization and were fol-
lowed by a third validation phase. In phase I, the main objective 
was to standardize radiomics feature definitions and to define 
reference values, in the absence of any additional image process-
ing. In phase II, we defined a general radiomics image processing 
scheme and obtained reference values for features under differ-
ent image processing configurations. In phase III, we assessed if 
the standardization conducted in the previous phases resulted in 
reproducible feature values for a validation data set.
Research Teams
We invited teams of radiomics researchers to collaborate in the 
IBSI. Participation was voluntary and open for the duration of 
the study. Teams were eligible if they (a) developed their own 
software for image processing and feature computation and (b) 
could participate in any phase of the study.
Radiomics Features
We defined a set of 174 radiomics features (Table 1). This set 
consisted of features commonly used to quantify the morpho-
logic characteristics, first-order statistical aspects, and spatial 
relationships between voxels (texture) in regions of 4inter-
est (ROIs) in three-dimensional images. To compute texture 
features, additional feature-specific parameters were required. 
This increased the number of computed features beyond 174 
(Appendix E1 [online]). All feature definitions are provided 
in chapter 3 of the IBSI reference manual (Appendix E2 
[online]).
General Radiomics Image Processing Scheme
We defined a general radiomics image processing scheme based 
on descriptions in the literature (3,6,17,20). The scheme con-
tained the main processing steps required for computation of 
features from a reconstructed image and is depicted in Figure 2. 
A full description of these image processing steps may be found 
in chapter 2 of the IBSI reference manual (online).
Data Sets
Each phase used a different data set. In phase I, we designed 
a small 80-voxel three-dimensional digital phantom with a 
74-voxel ROI mask to facilitate the process of establishing ref-
erence values for features, without involving image processing.
In phase II, we used a publicly available CT image in a pa-
tient with lung cancer. The accompanying segmentation of the 
gross tumor volume was used as the ROI (21).
The validation data set used in phase III consisted of a cohort 
of 51 patients with soft-tissue sarcoma who underwent multi-
modality imaging (coregistered CT, fluorine 18 fluorodeoxy-
glucose PET, and T1-weighted MRI) from the Cancer Imaging 
Archive (20,22,23). Each image was accompanied by a gross 
tumor volume segmentation, which was used as the ROI. PET 
and MRI were centrally preprocessed (Appendix E1 [online]) to 
ensure that standardized uptake value conversion and bias-field 
correction steps did not affect validation.
Defining Consensus on the Validity of Feature Reference 
Values
In the first two phases, research teams computed feature 
values from the ROI in the associated image data set directly 
(phase I) and according to predefined image processing param-
eters (phase II; Appendix E1 [online]). All of the most recent 
values submitted by each team were collected and limited to 
three significant digits. Then, we used the mode of the submit-
ted values for each feature as a tentative reference value.
We quantified the level of consensus on the validity of a ten-
tative reference value for each feature using two measures: (a) the 
number of research teams that submitted a value that matched 
the tentative reference value within a tolerance margin (Appen-
dix E1 [online]) and (b) the previous number divided by the 
total number of research teams that submitted a value.
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eral radiomics image processing scheme (24). At the start of 
the iterative process, we provided initial definitions for features 
(phase I) and the general radiomics image processing scheme 
(phase II) in a working document. For phase I, we manually 
calculated mathematically exact reference values for all but 
morphologic features to verify values produced by the research 
teams. For phase II, we defined five different image process-
ing configurations (configurations A–E) that covered a range 
of image processing parameters and methods commonly used 
in radiomics studies (Appendix E1 [online]).
After producing the initial working document, we asked the 
research teams to compute feature values from the ROI in the 
Four consensus levels were assigned based on the first consen-
sus measure as follows: less than three, weak; three to five, mod-
erate; six to nine, strong; 10 or more, very strong. The second 
measure assessed the stability of the consensus. We considered a 
tentative reference value for a feature to be valid only if it had at 
least moderate consensus and it was reproduced by an absolute 
majority (exceeding 50%) of the contributing research teams.
Iterative Standardization Process
In the first two phases, we iteratively refined consensus on the 
validity of feature reference values. This iterative process simul-
taneously served to standardize feature definitions and the gen-
Figure 1: Flowchart of study overview. The workflow in a typical radiomics analysis starts with acquisition and reconstruction of a medical 
image. Subsequently, the image is segmented to define regions of interest (ROI). Afterward, radiomics software is used to process the image 
and to compute features that characterize an ROI. We focused on standardizing the image processing and feature computation steps. Stan-
dardization was performed within two iterative phases. In phase I, we used a specially designed digital phantom to obtain reference values 
for radiomics features directly. In phase II, a publicly available CT image in a patient with lung cancer was used to obtain reference values 
for features under predefined configurations of a standardized general radiomics image processing scheme. Standardization of image 
processing and feature computation steps in radiomics software was prospectively validated during phase III by assessing reproducibility 
of standardized features in a publicly available multimodality patient cohort of 51 patients with soft-tissue sarcoma. 18F-FDG = fluorine 18 
fluorodeoxyglucose, T1w = T1-weighted.
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volume in each of the images in the soft-tissue sarcoma valida-
tion cohort using a realistic, predefined image processing con-
figuration (Appendix E1, [online]). The computed feature val-
ues were collected and processed centrally, as follows. First, for 
each team, we removed any feature that was not standardized 
by their software. To do so, we compared the reference values 
of the respective feature with the values that the team obtained 
from the CT image in the patient with lung cancer under im-
age processing configurations C, D, and E (as in phase II). If 
a value did not match its reference value, the feature was not 
used. The reproducibility of remaining standardized features 
was subsequently assessed using a two-way, random-effects, sin-
gle-rater, absolute agreement intraclass correlation coefficient 
(ICC) (25). Using the lower boundary of the 95% confidence 
interval of the ICC value (26), reproducibility of each feature 
was assigned to one of the following categories, as suggested by 
Koo and Li (27): poor, lower boundary less than 0.50; moder-
ate, lower boundary greater than or equal to 0.50 and less than 
0.75; good: lower boundary greater than 0.75 and less than 
0.90; excellent, lower boundary greater than 0.90.
Results
Characteristics of the Participating Research Teams
Twenty-five teams contributed to the IBSI (Fig 3; Appendix 
E1 [online]). Fifteen teams contributed to both standardization 
phases, and nine teams contributed to the validation phase. One 
team retired because they switched to software developed by an-
other team. Five teams implemented 95% or more of the defined 
features. Nine teams were able to compute features for all image 
processing configurations in phase II (Appendix E1 [online]).
The University Medical Center Groningen and the French 
National Institute of Health and Medical Research provided 
digital phantom (phase I) and from the ROI in the lung can-
cer CT image after image processing according to the different 
predefined image processing configurations (phase II). Feature 
values were collected and processed to analyze the consensus on 
the validity of tentative reference values. The results were then 
made available to all teams at an average interval of 4 weeks. The 
study leader would also contact the teams with feedback after 
comparing their submitted feature values with the mathemati-
cally exact values (phase I only) and with feature values obtained 
by other teams (phases I and II). The research teams provided 
feedback in the form of questions and suggestions concerning 
the descriptions in the working document and the standardiza-
tion of radiomics software. The working document was regularly 
updated as a result. Teams would then make changes to their 
software based on the results of the analysis and feedback from 
the study leader.
The two iterative phases were staggered to make it easier to 
separate differences and errors related to feature computation 
from those related to image processing. The initial contributions 
from phase I were analyzed in September 2016. We initiated 
phase II after achieving moderate or better consensus on the va-
lidity of reference values for at least 70% of the features, that is, 
time point 6 (January 2017). Initial contributions for phase II 
were analyzed at time point 10 (April 2017). Afterward, phases 
I and II were concurrent. We halted the iterative standardization 
process at time point 25 (March 2019) after we attained strong 
or better consensus on validity of reference values for more than 
90% of the features in both phases I and II. The overall timeline 
of the study is summarized in Appendix E1 (online).
Validation
After the standardization process finished, we asked the re-
search teams to compute 174 features from the gross tumor 
Table 1: Overview of Included Radiomics Features
Feature Family Base Definition
No. of Features
Phase I
Phase II Configuration  
A–B (2D)
Phase II Configuration  
C–E (3D) Phase III
Morphologic characteristics 29 29 29 29 29
Local intensity 2 2 2 2 2
Intensity-based statistics 18 18 18 18 18
Intensity histogram 23 23 23 23 23
Intensity-volume histogram 7 7 7 7 7
Gray-level co-occurrence matrix* 25 150 100 50 25
Gray-level run-length matrix* 16 96 64 32 16
Gray-level size-zone matrix* 16 48 32 16 16
Gray-level distance-zone matrix* 16 48 32 16 16
Neighborhood gray tone difference matrix* 5 15 10 5 5
Neighboring gray level dependence matrix* 17 51 34 17 17
Total 174 487 351 215 174
Note.—Data are numbers of features. A set of 174 radiomics features was standardized and validated in three phases. In phase I, features 
were computed without any prior image processing. In phase II, features were computed after image processing with five predefined con-
figurations (configurations A–E; image slice-based (two-dimensional [2D]) or volumetric (three-dimensional [3D]); Appendix E1 [online]). 
In the final phase III, we assessed the reproducibility of features standardized in phases I and II.
* Texture features have additional parameters that are required for their calculation, which increased the number of computed features  
(Appendix E1 [online]).
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three and two teams of research-
ers, respectively. This did not 
compromise consensus on the 
validity of feature reference val-
ues. Moderate, strong, or very 
strong consensus on the validity 
of the reference values was based 
on teams from at least three, 
five, and eight different top-
level institutions, respectively 
(Appendix E1 [online]).
Matlab (n = 10), C++ (n 
= 7), and Python (n = 5) were 
the most popular programming 
languages. No language depen-
dency was found; consensus of 
all features with a moderate or 
better consensus on the valid-
ity of their reference values was 
based on multiple program-
ming languages (Appendix E1 
[online]).
Consensus on Validity of 
Feature Reference Values
Consensus on the validity of fea-
ture reference values improved 
during the course of the study, 
as shown in Figure 4 and Table 
2. Initially, only weak consensus 
existed for the majority of fea-
tures: 232 of 302 (76.8%) and 
703 of 1075 (65.4%) for phase 
I and II, respectively.
At the final analysis time 
point, the number of features 
with a weak consensus had de-
creased to two of 487 (0.4%) 
for phase I and 19 of 1347 
(1.4%) for phase II. The re-
maining features with weak 
consensus on the validity of 
their (tentative) reference val-
ues were the area and volume 
densities of the oriented mini-
mum bounding box and the 
minimum volume enclosing el-
lipsoid (Appendix E1 [online]). 
We were unable to standardize 
the complex algorithms that are required to compute the ori-
ented minimum bounding box and minimum volume enclosing 
ellipsoid. Therefore, the previous features should not be regarded 
as standardized.
As shown in Table 2, strong or better consensus could be es-
tablished for 463 of 487 (95.1%) and 1220 of 1347 (90.6%) 
features in phases I and II, respectively. None of these features 
were found to be unstable. In phase II, two of 108 (1.9%) 
features with moderate consensus were unstable. Both were 
derived from the same feature: the area under the curve of the 
intensity-volume histogram. Hence, we do not consider this fea-
ture to be standardized.
The most commonly implemented features were mean, skew-
ness, excess kurtosis, and minimum of the intensity-based statistics 
family. These were implemented by 23 of 24 research teams. No 
feature was implemented by all teams (Appendix E1 [online]).
Figure 2: Flowchart of the general radiomics image processing scheme for computing radiomics features. Image pro-
cessing starts with reconstructed images. These images are processed through several optional steps: data conversion (eg, 
conversion to standardized uptake values), image postacquisition processing (eg, image denoising), and image interpola-
tion. Either the region of interest (ROI) is created automatically during the segmentation step, or an existing ROI is retrieved. 
The ROI is then interpolated as well, and intensity and morphologic masks are created as copies. The intensity mask may be 
resegmented according to intensity values to improve comparability of intensity ranges across a cohort. Radiomics features 
are then computed from the image masked by the ROI and its immediate neighborhood (local intensity features) or the ROI 
itself (all others). Image intensities are moreover discretized prior to computation of features from the intensity histogram (IH), 
intensity-volume histogram (IVH), gray-level co-occurrence matrix (GLCM), gray-level run-length matrix (GLRLM), gray-
level size-zone matrix (GLSZM), gray-level distance-zone matrix (GLDZM), neighborhood gray-tone difference matrix 
(NGTDM), and neighboring gray-level dependence matrix (NGLDM) families. All processing steps from image interpola-
tion to the computation of radiomics features were evaluated in this study.
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identified—for example, differences in interpolation, morpho-
logic representation of the ROI, and nomenclature differences—
and were subsequently resolved (Appendix E1 [online]). In ef-
fect, we cross-calibrated radiomics software implementations.
The demonstrated lack of initial correspondence between 
teams carries a clinical implication. Software implementations of 
seemingly well-defined mathematic formulas can vary greatly in 
the numeric results they produce. Clinical radiologists who are 
using advanced image analysis workstations should be aware of 
this, think critically about comparing results produced by differ-
ent workstations, and demand more details and validation stud-
ies from the vendors of those workstations.
Findings from most radiomics studies have not been trans-
lated into clinical practice, and they require external retrospec-
tive and prospective validation in clinical trials (2,28). The 
IBSI, in addition to the presented work, has defined reporting 
guidelines that indicate the elements that should be reported 
to facilitate this process. However, we refrained from creating 
a comprehensive recommendation on how to perform a good 
radiomics analysis for several reasons. First, such recommenda-
tions will need to be modality specific and possibly entity specific 
(29,30). The related specific evidence for the effect of particular 
Reproducibility of 
Standardized Features
We were able to find stable 
reference values with moder-
ate or better consensus for 169 
of 174 features. In the valida-
tion phase, most of these fea-
tures could be reproduced well 
(Fig 5, Appendix E1 [online]). 
Excellent reproducibility was 
found for 166 of 174, 164 of 
174, and 164 of 174 features 
for CT, PET, and MRI, re-
spectively. Good reproducibil-
ity was found for one of 174 
(CT) and three of 174 (PET 
and MRI) features. For each 
modality, two of 174 features 
had unknown reproducibil-
ity, which indicated that they 
were computed by fewer than 
two teams during validation. 
These features were Moran’s I 
index and Geary’s C measure. 
Although they were standard-
ized, they were expensive to 
compute. The remaining five 
of 174 features could not be 
standardized during the first 
two phases and were not as-
sessed during validation.
Discussion
In this study, the Image Bio-
marker Standardization Initia-
tive (IBSI) produced and validated a set of consensus-based 
reference values for radiomics features. Twenty-five research 
teams were able to standardize 169 of 174 features, which were 
subsequently shown to have good to excellent reproducibility 
in a validation data set.
With the completion of the current work, compliance with 
the IBSI standard can be checked for any radiomics software, 
as follows.
First, use the software to compute features using the digital 
phantom. Compare the resulting values against the reference 
values found in the IBSI reference manual and the compli-
ance check spreadsheet created for this purpose (Appendix E3 
[online]). Investigate any difference. Subsequently, resolve the 
differences or explain them (eg, the use of kurtosis instead of 
excess kurtosis).
Then repeat the previous steps with the CT data set used in 
this study and one or more of the image processing configura-
tions used in phase II.
Initial consensus on the validity of reference values for many 
features was weak, which means that teams obtained different 
values for the same feature. This mirrored findings reported 
elsewhere (15–18). Several notable causes of deviations were 
Figure 3: Bar graphs depict participation and radiomics feature coverage by research teams. A, Graph shows the num-
ber of research teams at each analysis time point during the two phases of the iterative standardization process. Teams com-
puted features without prior image processing (phase I) and after image processing (phase II), with the aim of finding refer-
ence values for a feature. Consensus on the validity of reference values was assessed at each time point, the time between 
which was variable (arbitrary unit [arb. unit]). B, Graph shows the final coverage of radiomics features implemented by 
each team in phase I, as well as the team’s ability to reproduce the reference value of a feature. We were unable to obtain 
reliable reference values for five features (no ref. value). The teams are listed in Appendix E1 (online). BCOM = Institute of 
Research and Technology b<>com, Brest; CaPTk = Cancer Imaging Phenomics Toolkit; CERR = Computational Environment 
for Radiological Research; KCL = King’s College London; LUMC = Leiden University Medical Center; MAASTRO = Maas-
tro, Maastricht, the Netherlands; MaCha = Marie-Charlotte Desseroit; MIRP = Medical Image Radiomics Processor; MITK 
= Medical Imaging Interaction Toolkit; QIFE = Quantitative Image Feature Engine; RaCaT = Radiomics Calculator; SERA = 
Standardized Environment for Radiomics Analysis; UCSF = University of California, San Francisco; UMCG = University Medi-
cal Center Groningen; USZ = University of Zurich.
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and image filters were not assessed (32), important modality-spe-
cific image processing steps were not benchmarked, and uncom-
mon image processing methods were not investigated. This is a 
serious limitation and one that the IBSI is currently addressing.
Despite the fact that standardized feature computation is 
an important step toward reproducible radiomics, the need for 
standardization and harmonization related to image acquisition, 
reconstruction, and segmentation remains, as these constitute 
additional sources of variability in radiomics studies. Because of 
this variability, features that can be reproduced from the same 
image using standardized radiomics software may nevertheless 
lack reproducibility in multicentric or multiscanner settings 
(14,19,33). We did not address these issues here as their compre-
hensive harmonization is the ongoing focus of other consortia 
and professional societies (2). Other approaches have also been 
proposed to address these issues, such as the reduction of cohort 
effects on radiomics features using statistical methods (34) and 
parameters, for example, the choice of interpolation algorithm, 
is far from complete. Second, recommendations or guidelines re-
garding parts of the radiomics analysis are already covered com-
prehensively elsewhere, for example, by the Transparent Report-
ing of a multivariable prediction model for Individual Prognosis 
or Diagnosis statement on diagnostic and prognostic modeling 
(31). Certainly, the image processing configurations used in 
phase II are not intended for general use, as their primary aim 
was to cover a range of different methods. Only the configura-
tions defined for the validation data set resemble a realistic set of 
parameters given the entity and imaging modalities.
Our study has several limitations. First, our aim was to lay 
a foundation for standardized computation of radiomics fea-
tures. To this end, we sought to standardize 174 commonly used 
features and to obtain reference values using image processing 
methods that radiomics researchers most commonly employ. To 
keep the scope manageable, many other features such as fractals 
Figure 4: Bar graphs depict iterative development of consensus on the validity of reference values for radiomics features. We tried to find reliable reference values for 
radiomics features in an iterative standardization process. In phase I, features were computed without prior image processing, whereas in phase II, features were assessed 
after image processing with five predefined configurations (configurations A–E; Appendix E1 [online]). The panels show, A, the overall development of consensus on the 
validity of (tentative) reference values in phases I and II and, B, the development of consensus in phase II, according to image processing configuration. Consensus on the 
validity of a reference value is based on the number of research teams that produce the same value for a feature (weak: 3; moderate: three to five; strong: six to nine; very 
strong: 10). We analyzed consensus at each of the analysis time points, the time between which was variable (arbitrary unit; arb. unit). New features were included at 
time points 5 and 22, causing an apparent decrease in consensus. For phase II, we first analyzed consensus at time point 10. Image processing configurations C and D 
were altered after time point 16. Configuration E was altered after revising the resegmentation processing step at time point 22. See Appendix E1 (online) for more informa-
tion regarding the timeline.
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In conclusion, the Image Biomarker Standardization Initia-
tive was able to produce and validate reference values for ra-
diomics features. These reference values enable verification of 
radiomics software, which will increase reproducibility of ra-
diomics studies and facilitate clinical translation of radiomics.
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Initial analysis  
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12 (25.0) 16 (5.3) 2 (12.5) 6 (2.0) 70 (23.2) 22 (7.3)








73 (21.3) 30 (2.8) 0 (0) 0 (0) 372 (34.6) 30 (2.8)








2 (2.0) 3 (1.4) 0 (0) 0 (0) 101 (47.0) 3 (1.4)








0 (0) 0 (0) 0 (0) 0 (0) 27 (12.6) 0 (0)








25 (22.3) 16 (7.4) 0 (0) 0 (0) 128 (59.5) 16 (7.4)








33 (52.4) 11 (5.1) 0 (0) 0 (0) 74 (34.4) 11 (5.1)








13 (31.0) 0 (0) 0 (0) 0 (0) 42 (19.5) 0 (0)
Final analysis  
 time point 
 Phase I 487 2 (0.4) 2 (0.4) 2 (100.0) 22 (4.5) 0 (0) 234  
(48.0)
0 (0) 229 (47.0) 485 (99.6) 463 (95.1)
 Phase II 1347 20 (1.5) 19 (1.4) 18 (94.7) 108 (8.0) 2 (1.9) 1152  
(85.5)
0 (0) 68 (5.0) 1328 (98.6) 1220 (90.6)
  Config A 351 4 (1.1) 4 (1.1) 3 (75.0) 22 (6.3) 1 (4.5) 307  
(87.5)
0 (0) 18 (5.1) 347 (98.9) 325 (92.6)
  Config B 351 5 (1.4) 4 (1.1) 4 (100.0) 24 (6.8) 1 (4.2) 317  
(90.3)
0 (0) 6 (1.7) 347 (98.9) 323 (92.0)
  Config C 215 4 (1.9) 4 (1.9) 4 (100.0) 9 (4.2) 0 (0) 171  
(79.5)
0 (0) 31 (14.4) 211 (98.1) 202 (94.0)
  Config D 215 4 (1.9) 4 (1.9) 4 (100.0) 6 (2.8) 0 (0) 192  
(89.3)
0 (0) 13 (6.0) 211 (98.1) 205 (95.3)
  Config E 215 3 (1.4) 3 (1.4) 3 (100.0) 47 (21.9) 0 (0) 165  
(76.7)
0 (0) 0 (0) 212 (98.6) 165 (76.7)
Note.—Data are number of features, with percentages in parentheses. Reference values of radiomics features were iteratively obtained in 
two phases. In phase I, features were computed without prior image processing, whereas in phase II, features were computed after image 
processing with five predefined configurations (configurations A–E; Appendix E1 [online]). Consensus on the validity of a reference value 
was based on the number of research teams that produced the same value (weak: 3; moderate: three to five; strong: six to nine; very 
strong: 10). Unstable features are those for which the consensus was only carried by a minority of teams (50%). Features with very 
strong consensus were never unstable, and the respective column was omitted. The number of features increased between the initial and 
final time points due to adding new features and computing features with additional feature-specific parameters (Appendix E1 [online]). 
Config = configuration.
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Figure 5: Bar graph shows reproducibility of standardized radiomics features. 
We assessed reproducibility of 169 standardized features on a validation cohort 
of 51 patients with soft-tissue sarcoma using multimodality imaging (CT, fluorine 
18 fluorodeoxyglucose PET, and T1-weighted MRI; shown as CT, PET and MRI) 
according to the feature values computed by research teams. We assigned each 
feature to a reproducibility category based on the lower boundary of the 95% 
confidence interval of the two-way random effects, single rater, absolute agree-
ment intraclass correlation coefficient of the feature (poor: ,0.50; moderate: 
0.50–0.75; good: 0.75–0.90; excellent: 0.90). Five features could not be stan-
dardized in this study. Two features with unknown reproducibility were computed 
by fewer than two teams during validation.
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